Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Type I interferon is induced by hemolysis and drives antibody-mediated erythrophagocytosis in sickle cell disease

Yunfeng Liu, Mouli Pal, Weili Bao, Patricia A. Shi, Cheryl A. Lobo, Xiuli An, Deepa Manwani, Hui Zhong, Karina Yazdanbakhsh

Blood (2021) 138 (13): 1162–1171.

https://doi.org/10.1182/blood.2021011629

Published: 2021

Includes: Supplemental data

Journal Articles

Classical Monocyte Deficiency Calculated By the Mono-Index Can Predict Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Vinicius Campos de Molla, MD, Matheus Vescovi Gonçalves, MD PhD, Elisa Y Kimura, Vergilio Colturato, MD, Maura V Ikoma, MD PhD, Victor Gottardello Zecchin, MD, Adriana Seber, MD, Nelson Hamerschlak, MD PhD, Vanderson Rocha, MD PhD, Yana Novis, MD, Mihoko Yamamoto, MD PhD, Marcio Nucci, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 5666.

https://doi.org/10.1182/blood-2019-126221

Published: 2019

Journal Articles

The Absolute Count of Circulating, Classical, CD14 ++ /CD16 - Monocytes Is a Poor Prognosis Marker in Chronic Myelomonocytic Leukemia (CMML)

Matthieu Jestin, Sihem Tarfi, PharmD, Bouchra Badaoui, PharmD, Nicolas Freynet, PharmD, Ivan Sloma, PharmD,PhD, Margot Morabito, Sébastien Maury, MD PhD, Pierre Fenaux, MD PhD, Eric Solary, MD PhD, Dorothée Selimoglu-Buet, PhD, Orianne Wagner Ballon, MD PhD

Blood (2019) 134 (Supplement_1): 4242.

https://doi.org/10.1182/blood-2019-121794

Published: 2019

Journal Articles

Inflammation Response Cytokines IFN-γ and IL-10 Regulate Monocyte Subset Differentiation

Hui Zhong, PhD, Weili Bao, Yunfeng Liu, PhD, Karina Yazdanbakhsh, PhD

Blood (2019) 134 (Supplement_1): 3586.

https://doi.org/10.1182/blood-2019-129515

Published: 2019

Journal Articles

Disappearance of Slan-Positive Non-Classical Monocytes As a New Parameter for the Diagnosis of Chronic Myelomonocytic Leukemia with Associated Inflammatory State

Sihem Tarfi, PharmD, Bouchra Badaoui, PharmD, Nicolas Freynet, PharmD, Margot Morabito, Jeffie Lafosse, Andrea Toma, MD PhD, Pierre Fenaux, MD PhD, Eric Solary, MD PhD, Dorothée Selimoglu-Buet, PhD, Orianne Wagner Ballon, MD PhD

Blood (2018) 132 (Supplement 1): 4376.

https://doi.org/10.1182/blood-2018-99-116451

Published: 2018

Journal Articles

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

Blood (2018) 132 (Supplement 1): 600.

https://doi.org/10.1182/blood-2018-99-113095

Published: 2018

Journal Articles

Risk Factors and Outcomes of Deep Vein Thrombosis in Pediatric Osteomyelitis

Maria Ahmad, MBBS, Christine M. Knoll, MD, Sanjay J. Shah, MBBS, Lucia Mirea, PhD

Blood (2018) 132 (Supplement 1): 5054.

https://doi.org/10.1182/blood-2018-99-111411

Published: 2018

Journal Articles

Improving Access to Care for Adults with Sickle Cell Disease in Los Angeles County

Susan Claster, MD, Ellen Rothman, Mary Brown, Judith Baker, DrPH, MHSA, Diane J. Nugent, MD

Blood (2017) 130 (Supplement 1): 4656.

https://doi.org/10.1182/blood.V130.Suppl_1.4656.4656

Published: 2017

Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

Catherine Thieblemont, MD PhD, Anastasios Stathis, MD, Giorgio Inghirami, MD, Lionel Karlin, Franck Morschhauser, MD PhD, Mary Gleeson, FRCPath, Florence Broussais, MD, Sandy Amorim, MD, Gilles Salles, MDPhD, Thierry Facon, MD, David Cunningham, FMedSci, Norbert Vey, MD PhD, Fabrice Bourdel, MSc, Patrice Herait, MD, Emanuele Zucca, MD

Blood (2014) 124 (21): 4417.

https://doi.org/10.1182/blood.V124.21.4417.4417

Published: 2014

Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

Hervé Dombret, MD PhD, Claude Preudhomme, MD PhD, Céline Berthon, MD, Emmanuel Raffoux, MD, Xavier Thomas, MD PhD, Norbert Vey, MDPhD, Carlos Gomez-Roca, MD, Mark Ethell, MD, Karen Yee, MD, Fabrice Bourdel, MSc, Patrice Herait, MD PhD, Mauricette Michallet, MD PhD, Christian Recher, MDPhD, Christophe Roumier, Bruno Quesnel, MD

Blood (2014) 124 (21): 117.

https://doi.org/10.1182/blood.V124.21.117.117

Published: 2014

Journal Articles

Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation

Maria Eugenia Riveiro, PhD, Lucile Astorgues-Xerri, PhD, Charlotte Canet-jourdan, Mohamed Bekradda, MD, Esteban Cvitkovic, MD, Patrice Herait, MD, Eric Raymond, MD PhD

Blood (2014) 124 (21): 873.

https://doi.org/10.1182/blood.V124.21.873.873

Published: 2014

Journal Articles

Combinatorial Anti-Leukemic Activity Of Liposomal Ceramide and Inhibitors Of Autophagy

Brian Barth, Ph.D., Nicole Keasey, PhD, Lindsey Fisher, Bsc, Megan Young, Bsc, Stephan Stern, PhD, Thomas P. Loughran, Jr., MD, Mark Kester, PhD, Hong-Gang Wang, PhD, David F. Claxton, MD

Blood (2013) 122 (21): 2694.

https://doi.org/10.1182/blood.V122.21.2694.2694

Published: 2013

Journal Articles

Targeting Sphingosine Kinase 1 in NK-LGL Leukemia

Francis LeBlanc, Xin Liu, MD, PhD, Todd Fox, PhD, Mithun Shah, MD, PhD, Andrew Rogers, Lindsay Ryland, PhD, Mark Kester, PhD, Jong Yun, PhD, Thomas P. Loughran, Jr., MD

Blood (2012) 120 (21): 1313.

https://doi.org/10.1182/blood.V120.21.1313.1313

Published: 2012

Journal Articles

PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts

Violeta Chitu, Viorel Nacu, Julia F. Charles, William M. Henne, Harvey T. McMahon, Sayan Nandi, Halley Ketchum, Renee Harris, Mary C. Nakamura, E. Richard Stanley

Blood (2012) 120 (15): 3126–3135.

https://doi.org/10.1182/blood-2012-04-425595

Published: 2012

Includes: Supplemental data

Journal Articles

PSTPIP2 Limits Osteoclast Precursor Differentiation and Inflammation-Associated Bone Loss.

Violeta Chitu, Viorel Nacu, Julia F Charles, Halley Ketchum, Cristopher Haskell, Sayan Nandi, E. Richard Stanley

Blood (2010) 116 (21): 1489.

https://doi.org/10.1182/blood.V116.21.1489.1489

Published: 2010

Journal Articles

Primed innate immunity leads to autoinflammatory disease in PSTPIP2-deficient cmo mice

Violeta Chitu, Polly J. Ferguson, Rosalie de Bruijn, Annette J. Schlueter, Luis A. Ochoa, Thomas J. Waldschmidt, Yee-Guide Yeung, E. Richard Stanley

Blood (2009) 114 (12): 2497–2505.

https://doi.org/10.1182/blood-2009-02-204925

Published: 2009

Includes: Supplemental data

Journal Articles

Human T-cell leukemia virus type 2 induces survival and proliferation of CD34 + TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-γ and granulocyte macrophage–colony-stimulating factor

Chiara Bovolenta, Elisabetta Pilotti, Massimiliano Mauri, Marco Turci, Paolo Ciancianaini, Paola Fisicaro, Umberto Bertazzoni, Guido Poli, Claudio Casoli

Blood (2002) 99 (1): 224–231.

https://doi.org/10.1182/blood.V99.1.224

Published: 2002

NARROW

Type I interferon is induced by hemolysis and drives antibody-mediated erythrophagocytosis in sickle cell disease

Classical Monocyte Deficiency Calculated By the Mono-Index Can Predict Mortality in Allogeneic Hematopoietic Stem Cell Transplantation Patients

The Absolute Count of Circulating, Classical, CD14 ++ /CD16 - Monocytes Is a Poor Prognosis Marker in Chronic Myelomonocytic Leukemia (CMML)

Inflammation Response Cytokines IFN-γ and IL-10 Regulate Monocyte Subset Differentiation

Disappearance of Slan-Positive Non-Classical Monocytes As a New Parameter for the Diagnosis of Chronic Myelomonocytic Leukemia with Associated Inflammatory State

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

Risk Factors and Outcomes of Deep Vein Thrombosis in Pediatric Osteomyelitis

Improving Access to Care for Adults with Sickle Cell Disease in Los Angeles County

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation

Combinatorial Anti-Leukemic Activity Of Liposomal Ceramide and Inhibitors Of Autophagy

Targeting Sphingosine Kinase 1 in NK-LGL Leukemia

PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts

PSTPIP2 Limits Osteoclast Precursor Differentiation and Inflammation-Associated Bone Loss.

Primed innate immunity leads to autoinflammatory disease in PSTPIP2-deficient cmo mice

Human T-cell leukemia virus type 2 induces survival and proliferation of CD34 + TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-γ and granulocyte macrophage–colony-stimulating factor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only